Suppr超能文献

2-氯脱氧腺苷治疗毛细胞白血病后完全缓解的评估:骨髓免疫染色的效用及脾指数的测量

Assessment of complete remission after 2-chlorodeoxyadenosine for hairy cell leukemia: utility of marrow immunostaining and measurement of splenic index.

作者信息

Tallman M S, Hakimian D, Dyrda S, Kiley C, Nemcek A, Peterson L

机构信息

Robert H. Lurie Cancer Center, Northwestern University, Chicago, IL 60611.

出版信息

Leuk Lymphoma. 1994;14 Suppl 1:133-8.

PMID:7529609
Abstract

2-Chlorodeoxyadenosine (2-CdA) yields high complete remission (CR) rates in patients with hairy cell leukemia (HCL) Two approaches were used to detect minimal residual disease. We studied two B-lineage antibodies, L26 and MB2, and a T-lineage antibody, UCHL-1, in fixed marrow core biopsies from 34 patients with HCL before and after 2-CdA to detect minimal residual in the marrow. In addition, the splenic index was calculated before and after treatment to detect residual splenomegaly. Prior to therapy, hairy cells exhibited intense cytoplasmic membrane reactivity with L26 and strong intracytoplasmic reactivity with MB2. UCHL-1 did not react with hairy cells. Thirty-one patients were assessable 3 months after therapy. Five of 24 (21%) patients in CR by routine evaluation had residual HCL detected by immunostaining. Four of these 5 patients have been reevaluated at 1 year. One patient relapsed by routine evaluation, 2 remained positive by immunostaining alone, and 1 patient became negative by immunostaining. A total of 19 patients have been evaluated at 1 year and 17 remain in CR. Three of these 17 were positive by immunostaining, 2 of whom had been positive at 3 months and 1 additional patient who became positive by immunostaining at 1 year. Of 9 patients evaluated at 2 years, an additional 2 of 3 patients with minimal residual disease detected previously by immunostaining at 3 months relapsed by routine morphology and 1 had persistent positive immunostaining. Only 1 patient in remission by morphology and immunostaining has relapsed.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

2-氯脱氧腺苷(2-CdA)可使毛细胞白血病(HCL)患者获得较高的完全缓解(CR)率。采用两种方法检测微小残留病。我们研究了两种B系抗体L26和MB2以及一种T系抗体UCHL-1,用于检测34例接受2-CdA治疗前后的HCL患者固定骨髓芯活检中的骨髓微小残留病。此外,计算治疗前后的脾脏指数以检测残留脾肿大。治疗前,毛细胞与L26表现出强烈的细胞质膜反应性,与MB2表现出强烈的细胞质内反应性。UCHL-1不与毛细胞反应。31例患者在治疗后3个月可进行评估。常规评估达到CR的24例患者中有5例(21%)通过免疫染色检测到残留HCL。这5例患者中有4例在1年时进行了重新评估。1例患者通过常规评估复发,2例仅免疫染色仍为阳性,1例患者免疫染色转为阴性。共有19例患者在1年时进行了评估,17例仍处于CR状态。这17例中有3例免疫染色为阳性,其中2例在3个月时为阳性,另外1例患者在1年时免疫染色转为阳性。在2年时评估的9例患者中,3例在3个月时通过免疫染色检测到微小残留病的患者中,又有2例因常规形态学复发,1例免疫染色持续阳性。仅1例形态学和免疫染色均缓解的患者复发。(摘要截断于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验